UBS Group
DMIIR

UBS Group’s Drugs Made In America Acquisition II Corp Right DMIIR Stock Holding History

UBS Group’s Portfolio DMIIR Stock Details DMIIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20 Hold
251
– – ﹤0.01% 10280
2026
Q1 		$20 Buy
+251
New +$29 ﹤0.01% 10297

Other funds holding DMIIR

MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
TCM
Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $507M AUM 6.15% 1-Year Est. Return

UBS Group's DMIIR Position: Q2 2026 in Review

UBS Group held its Drugs Made In America Acquisition II Corp Right (DMIIR) position steady in Q2 2026 at 251 shares worth $20. The position accounts for ﹤0.01% of the portfolio, ranked #10280.

UBS Group first reported a position in DMIIR in Q1 2026 and has held it in 2 quarters since. 61 funds tracked by Wall St. Rank hold DMIIR as of Q2 2026.

  • UBS Group held 251 shares of Drugs Made In America Acquisition II Corp Right worth $20 as of Q2 2026.
  • UBS Group left its Drugs Made In America Acquisition II Corp Right share count unchanged in Q2 2026.
  • Drugs Made In America Acquisition II Corp Right made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #10280 holding.
  • UBS Group first reported a position in Drugs Made In America Acquisition II Corp Right in Q1 2026 and has held it in 2 quarters since.
  • 61 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp Right as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.